| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/31/2023 | 89.83% | Stifel | → $25 | Initiates Coverage On | → Buy |
| 07/13/2022 | 120.2% | Credit Suisse | $27 → $29 | Maintains | Outperform |
| 07/12/2022 | 127.79% | Cantor Fitzgerald | → $30 | Initiates Coverage On | → Overweight |
| 02/25/2022 | 105.01% | Credit Suisse | $25 → $27 | Maintains | Outperform |
| 02/25/2022 | 112.6% | SVB Leerink | $41 → $28 | Maintains | Outperform |
| 02/15/2022 | 165.76% | Jefferies | → $35 | Initiates Coverage On | → Buy |
| 11/26/2021 | 59.45% | Credit Suisse | $40 → $21 | Maintains | Outperform |
| 11/24/2021 | 142.98% | HC Wainwright & Co. | $43 → $32 | Maintains | Buy |
| 08/06/2021 | 203.72% | Credit Suisse | $42 → $40 | Maintains | Outperform |
| 08/06/2021 | 211.31% | SVB Leerink | $40 → $41 | Maintains | Outperform |
| 02/26/2021 | 203.72% | SVB Leerink | $42 → $40 | Maintains | Outperform |
| 02/24/2021 | 226.5% | HC Wainwright & Co. | $45 → $43 | Maintains | Buy |
| 12/07/2020 | 241.69% | HC Wainwright & Co. | $40 → $45 | Maintains | Buy |
| 12/03/2020 | 241.69% | Stifel | → $45 | Initiates Coverage On | → Buy |
| 10/12/2020 | 203.72% | HC Wainwright & Co. | $22 → $40 | Maintains | Buy |
| 10/08/2020 | 226.5% | Credit Suisse | $27 → $43 | Maintains | Outperform |
| 07/07/2020 | 105.01% | Credit Suisse | → $27 | Initiates Coverage On | → Outperform |
| 06/01/2020 | 105.01% | Oppenheimer | $23 → $27 | Maintains | Outperform |
| 05/06/2020 | 112.6% | Wedbush | $30 → $28 | Maintains | Outperform |
| 05/05/2020 | 74.64% | Oppenheimer | $27 → $23 | Maintains | Outperform |
| 05/05/2020 | 67.05% | HC Wainwright & Co. | $29 → $22 | Reiterates | → Buy |
| 05/05/2020 | 82.23% | Barclays | → $24 | Initiates Coverage On | → Overweight |
| 09/05/2019 | 67.05% | JMP Securities | → $22 | Reinstates | → Market Outperform |
| 07/18/2019 | 112.6% | Deutsche Bank | → $28 | Initiates Coverage On | → Buy |
| 11/09/2018 | 89.83% | Piper Sandler | → $25 | Initiates Coverage On | → Overweight |
| 08/01/2018 | 135.38% | HC Wainwright & Co. | → $31 | Initiates Coverage On | → Buy |
What is the target price for Kura Oncology (KURA)?
The latest price target for Kura Oncology (NASDAQ: KURA) was reported by Stifel on January 31, 2023. The analyst firm set a price target for $25.00 expecting KURA to rise to within 12 months (a possible 89.83% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Kura Oncology (KURA)?
The latest analyst rating for Kura Oncology (NASDAQ: KURA) was provided by Stifel, and Kura Oncology initiated their buy rating.
When is the next analyst rating going to be posted or updated for Kura Oncology (KURA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kura Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kura Oncology was filed on January 31, 2023 so you should expect the next rating to be made available sometime around January 31, 2024.
Is the Analyst Rating Kura Oncology (KURA) correct?
While ratings are subjective and will change, the latest Kura Oncology (KURA) rating was a initiated with a price target of $0.00 to $25.00. The current price Kura Oncology (KURA) is trading at is $13.17, which is within the analyst's predicted range.